451 related articles for article (PubMed ID: 25413383)
1. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
2. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
3. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
[TBL] [Abstract][Full Text] [Related]
4. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
5. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Helin TA; Pakkanen A; Lassila R; Joutsi-Korhonen L
Clin Chem; 2013 May; 59(5):807-14. PubMed ID: 23378569
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
7. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
8. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
9. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
10. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
Lim MS; Chapman K; Swanepoel P; Enjeti AK
Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
[TBL] [Abstract][Full Text] [Related]
12. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
Douxfils J; Chatelain B; Hjemdahl P; Devalet B; Sennesael AL; Wallemacq P; Rönquist-Nii Y; Pohanka A; Dogné JM; Mullier F
Thromb Res; 2015 May; 135(5):852-60. PubMed ID: 25743887
[TBL] [Abstract][Full Text] [Related]
13. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
14. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
[TBL] [Abstract][Full Text] [Related]
15. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Samama MM; Guinet C; Le Flem L; Ninin E; Debue JM
J Thromb Thrombolysis; 2013 Feb; 35(2):140-6. PubMed ID: 23335022
[TBL] [Abstract][Full Text] [Related]
16. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
Baglin T; Keeling D; Kitchen S;
Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
[No Abstract] [Full Text] [Related]
17. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
Douxfils J; Mullier F; Loosen C; Chatelain C; Chatelain B; Dogné JM
Thromb Res; 2012 Dec; 130(6):956-66. PubMed ID: 23006523
[TBL] [Abstract][Full Text] [Related]
19. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
20. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
